"Viral Load" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
| Descriptor ID |
D019562
|
| MeSH Number(s) |
E01.370.225.875.950 E05.200.875.950 G06.920.850
|
| Concept/Terms |
Viral Load- Viral Load
- Load, Viral
- Viral Burden
- Burden, Viral
|
Below are MeSH descriptors whose meaning is more general than "Viral Load".
Below are MeSH descriptors whose meaning is more specific than "Viral Load".
This graph shows the total number of publications written about "Viral Load" by people in this website by year, and whether "Viral Load" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 9 | 9 |
| 2003 | 2 | 5 | 7 |
| 2004 | 0 | 6 | 6 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 6 | 6 |
| 2007 | 0 | 8 | 8 |
| 2008 | 0 | 8 | 8 |
| 2009 | 2 | 7 | 9 |
| 2010 | 1 | 12 | 13 |
| 2011 | 0 | 11 | 11 |
| 2012 | 1 | 8 | 9 |
| 2013 | 5 | 11 | 16 |
| 2014 | 2 | 15 | 17 |
| 2015 | 8 | 14 | 22 |
| 2016 | 3 | 13 | 16 |
| 2017 | 7 | 15 | 22 |
| 2018 | 5 | 15 | 20 |
| 2019 | 2 | 6 | 8 |
| 2020 | 3 | 10 | 13 |
| 2021 | 3 | 10 | 13 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 4 | 7 | 11 |
| 2025 | 4 | 6 | 10 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Load" by people in Profiles.
-
Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. J Int AIDS Soc. 2026 May; 29(5):e70108.
-
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. J Antimicrob Chemother. 2026 Mar 04; 81(4).
-
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20?years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar; 162:108213.
-
Novel application of dried blood spot tenofovir diphosphate to predict viral suppression in postpartum women with HIV in Malawi. AIDS. 2026 May 01; 40(5):589-599.
-
Retention in HIV Care Still Matters: A Longitudinal Multisite Analysis. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):123-130.
-
In Vivo Characterization and Tissue Tropism of a Wild-Type Yellow Fever Virus Isolate from the 2017-2018 Brazilian Outbreak in C57BL/6 IFNAR1-/- Mice. Viruses. 2025 Sep 29; 17(10).
-
Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis. Lancet. 2025 Jul 26; 406(10501):349-357.
-
Household clusters of SARS-CoV-2 Omicron subvariants contemporaneously sequenced from dogs and their owners. mSphere. 2025 Jul 29; 10(7):e0007425.
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19. JCI Insight. 2025 Jul 08; 10(13).